Altitude Crest Partners’s Immunome IMNM Stock Holding History

Altitude Crest Partners’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-262,284	Closed	-$6.47M	–	16
2024 Q1	$6.47M	Buy	+262,284	New	+$5.32M	2.77%	13

Other funds holding IMNM

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Altitude Crest Partners's IMNM Position: Q2 2024 in Review

Altitude Crest Partners sold out of Immunome (IMNM) in Q2 2024, closing a stake of 262,284 shares — an estimated $6.47M sold.

Altitude Crest Partners first reported a position in IMNM in Q1 2024 and held it in 1 quarter. The position peaked at $6.47M in Q1 2024. 113 funds tracked by Wall St. Rank hold IMNM as of Q2 2024.

Altitude Crest Partners reported no remaining Immunome position as of Q2 2024 after selling out during the quarter.
Altitude Crest Partners sold 262,284 Immunome shares in Q2 2024, an estimated $6.47M.
Altitude Crest Partners first reported a position in Immunome in Q1 2024 and held it in 1 quarter.
Altitude Crest Partners's Immunome position peaked at $6.47M in Q1 2024.
113 funds tracked by Wall St. Rank held Immunome as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.